Lexaria Bioscience Corp. LEXX Archives - Page 12 of 39

ThursdayJul 20, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Building a Robust and Growing International Patent Portfolio for DehydraTECH(TM) in Support of Commercial Opportunities

Lexaria is a global innovator in drug delivery platforms with an expanding portfolio of patents that currently stands at 34 granted patents and many patents pending worldwide These patents pertain to the company’s method of improving bioavailability and taste as well as the use of DehydraTECH(TM) as a delivery platform for a wide variety of active pharmaceutical ingredients (“APIs”) The company has, since June 2015, simultaneously filed the US utility patent application and an international patent application under the Patent Cooperation Treaty (“PCT”) procedure, both through the USPTO The PCT procedure has made the process of initiating international patent applications…

WednesdayJul 19, 2023 11:55 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sector

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it was granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office (“USPTO”). According to the update, U.S. patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. The company’s superior DehydraTECH processing and sublingual compositions have now been recognized through exceptional scientific study results as well as…

FridayJul 14, 2023 2:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Study Reveals ‘Most Convincing Evidence’ of CBD’s Anti-Inflammatory Actions in Humans

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced additional findings from its human clinical study HYPER-H21-4, completed last year. “The hypertension study sought to evaluate DehydraTECH-processed cannabidiol (“CBD”) as a potential antihypertensive medication and already achieved primary efficacy and safety objectives. According to the company, the study also demonstrated significant reductions in several pro-inflammatory biomarkers – interleukin (‘IL’) 8, 10 and 18 – known to be linked to cardiovascular disease (‘CVD’) and many other conditions such as asthma, lung diseases, chronic kidney disease, fatty liver disease, type 1 and 2 diabetes, obesity, and rheumatoid arthritis. More specifically, after five weeks of…

FridayJul 14, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments

The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11% Drug developers are shifting focus to the development of lipophilic drug compounds, which increases bioavailability DehydraTECH-enabled drugs improve the speed of onset, increase bioavailability, increases brain absorption, and reduces drug administration costs Lexaria’s DehydraTECH has 34 patents granted worldwide and many more pending across several categories of fat-soluble active molecules and drugs The company operates through four separate subsidiaries to explore the potential and options for the use of DehydraTECH in respective industries Bioavailability is the ability of…

TuesdayJul 11, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023 The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations Lexaria looks to build on the momentum gathered so far, and its management is…

MondayJul 03, 2023 12:01 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL…

FridayJun 30, 2023 2:36 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight

Lexaria’s latest peer-reviewed publications were published in June 2023 in the International Journal of Molecular Sciences, Advances in Therapy, and Biomedicine & Pharmacotherapy Lexaria’s eight peer-reviewed publications support the company’s pursuit of launching an FDA-registered IND program to formally investigate DehydraTECH(TM)-CBD for hypertension The global cardiovascular drug market was worth $146.5 billion and is expected to reach $173.5 billion in 2026 – making patent protection crucial in commercial markets To date, Lexaria has a robust intellectual property portfolio with 34 patents granted and many more pending worldwide Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced…

WednesdayJun 28, 2023 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US

Lexaria Bioscience recently received four new patents granted in Canada and the United States In the U.S., the company received two new hypertension-related patents expected to be of particular importance as the company pursues FDA approval for a Phase 1b study evaluating DehydraTECH(TM)-processed CBD So far, the company has a robust intellectual property portfolio comprising 34 patents granted worldwide The strong portfolio gives the company the necessary impetus and peace of mind to pursue multiple large markets, starting with the multi-billion dollar cardiovascular drugs market The company has conducted five human clinical studies that have provided insights into the potential…

ThursdayJun 22, 2023 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Findings in Diabetes Animal Study and Two Other R&D Programs

Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same results of Epidiolex(R) in the company’s animal epilepsy study Dementia – Lexaria determined that a longer testing duration is needed for DehydraTECH-CBD in cognition studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented DehydraTECH(TM) technology, recently reported additional findings from its diabetes animal study DIAB-A22-1, as well as updates on two other applied R&D programs for dementia (DEM-A22-1) and epilepsy (EPIL-A21-1). In March, Lexaria announced that it had…

TuesdayJun 20, 2023 2:10 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof, and No. 8 in its: Compositions Infused with Nicotine Compounds and Methods of Use Thereof. Lexaria was also granted two new U.S. patents under its patent family No. 21. The first being for Pharmaceutical Compositions and Methods for Treating Hypertension, as well as the second being for Compositions and Methods…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX